专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08574828B2 Controlled platelet activation to monitor therapy of ADP antagonists 有权
标题翻译：控制血小板活化以监测ADP拮抗剂的治疗
公开(公告)号：US08574828B2
公开(公告)日：2013-11-05
申请号：US12876730
申请日：2010-09-07
申请人： Barry S Coller , Dennis Durbin
发明人： Barry S Coller , Dennis Durbin
IPC分类号： C12Q1/00
CPC分类号： G01N33/86
摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.
摘要翻译：提供一种确定个体是否由于抑制血小板活化起始，信号转导和/或GPIIb / IIIa阻断而形成血小板血栓形成能力降低的方法。从被评估的个体获得血液样本。血液样品与1）抗凝剂混合; 2）足够的缓冲液将抗凝血液的pH和盐浓度保持在适合血小板聚集的范围内; 3）固定在固体表面上的血小板GPIIb / IIIa受体配体; 4）增强信号转导途径的一种或多种药物和5）受体激活剂。将该组合在凝集颗粒的条件下孵育。在搅拌的混合物中评估血小板介导的凝集。没有凝集表明个体具有降低形成血小板血栓的能力。

2. 发明申请

US20120190645A1 Organic compounds 有权
标题翻译：有机化合物
公开(公告)号：US20120190645A1
公开(公告)日：2012-07-26
申请号：US13441412
申请日：2012-04-06
申请人： Robert Blue , Barry S. Coller
发明人： Robert Blue , Barry S. Coller
IPC分类号： A61K31/727 , A61P7/02 , A61K31/519
CPC分类号： C07D513/04 , A61K31/519
摘要： The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
摘要翻译：本发明涉及可用于抑制和/或减少血小板沉积，粘附和/或聚集的化合物和组合物。本发明还涉及用于筛选用于抑制或减少血小板沉积，粘附和/或聚集的化合物和组合物的方法。本发明还涉及用于治疗或预防血栓形成障碍的方法，包括中风，心肌梗死，不稳定型心绞痛，外周血管疾病，血管成形术或支架放置后的突然闭合以及血管手术导致的血栓形成。

3. 发明授权

US08173661B2 Alpha-IIB-beta-3 inhibitors and uses thereof 有权
标题翻译： α-IIB-β-3抑制剂及其用途
公开(公告)号：US08173661B2
公开(公告)日：2012-05-08
申请号：US12514286
申请日：2007-11-08
申请人： Robert Blue , Barry S. Coller
发明人： Robert Blue , Barry S. Coller
IPC分类号： A01N43/90 , A61K31/519 , C07D471/00 , C07D487/00 , C07D491/00
CPC分类号： C07D513/04 , A61K31/519
摘要： The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
摘要翻译：本发明涉及可用于抑制和/或减少血小板沉积，粘附和/或聚集的化合物和组合物。本发明还涉及用于筛选用于抑制或减少血小板沉积，粘附和/或聚集的化合物和组合物的方法。本发明还涉及用于治疗或预防血栓形成障碍的方法，包括中风，心肌梗死，不稳定型心绞痛，外周血管疾病，血管成形术或支架放置后的突然闭合以及血管手术导致的血栓形成。

4. 发明授权

US5854005A Platelet blockade assay 失效
标题翻译：血小板阻断试验
公开(公告)号：US5854005A
公开(公告)日：1998-12-29
申请号：US754773
申请日：1996-11-20
申请人： Barry S. Coller
发明人： Barry S. Coller
IPC分类号： G01N33/50 , G01N33/86 , G01N33/546 , G01N33/552
CPC分类号： G01N33/86 , G01N33/5091 , Y10S435/975
摘要： The present invention is an assay for determining glycoprotein IIb/IIIa receptor blockade in whole blood. Agglutinization of small polymeric beads coated with a glycoprotein IIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein IIb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade of the GPIIb/IIIa receptors has been achieved. In a preferred embodiment, the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at the bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the glycoprotein IIb/IIIa receptors are not blocked.
摘要翻译：本发明是用于测定全血中糖蛋白IIb / IIIa受体阻断的测定方法。当珠粒与含有未被阻断的糖蛋白IIb / IIIa受体的全血血小板接触时，会结合涂有糖蛋白IIb / IIIa配体如纤维蛋白原的小聚合物珠粒的凝集。未凝聚表明GPIIb / IIIa受体的阻断已经实现。在一个优选的实施方案中，加入凝血酶受体激活剂导致快速和方便的测定，足以在床边进行，并导致小聚合物珠粒在方便的已知时间段内凝集，如果糖蛋白IIb / IIIa受体不被阻断。

5. 发明授权

US5338725A Anti-aggregatory agents for platelets 失效
公开(公告)号：US5338725A
公开(公告)日：1994-08-16
申请号：US906525
申请日：1992-06-30
申请人： Iwao Ojima , Masakatsu Eguchi , Young-Im Oh , Barry S. Coller
发明人： Iwao Ojima , Masakatsu Eguchi , Young-Im Oh , Barry S. Coller
IPC分类号： A61K38/00 , C07K7/02 , C07K14/75 , A61K37/02 , C07K7/06 , C07K7/08
CPC分类号： C07K14/75 , C07K7/02 , A61K38/00
摘要： The present invention provides synthetic antiaggregatory agents for preventing inhibition of fibrinogen-platelet binding. These anti-aggregatory agents have the general formulas (1)-(5).H--[--(AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.j --].sub.n --Cx (1)[Ri--C(O)--R--G--D--(AA.sub.j).sub.j --].sub.n --CX (2)Cy--[--AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.i --].sub.n --Z (3)H--[--(AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.j --].sub.n --CZ--[--(AA.sub.k).sub.k --R--G--D--(AA.sub.l).sub.l --].sub.m --Z (4)[R.sub.1 --C(O)--R--G--D--(AA.sub.i).sub.i --].sub.n --CZ[--(AA.sub.j).sub.j ]--R--G--D--(AA.sub.k).sub.k --].sub.m --Z (5)in which: R=Arg; G=Gly; D=Asp; AA.sub.i, AA.sub.j, AA.sub.k and AA.sub.l = alpha-, beta- and omega-amino acid residues; (AA.sub.i).sub.i (AA.sub.j).sub.j =peptide chains having the same or different amino acid residues; (AA.sub.k).sub.k =peptide chains having the same or different amino acid residues; (AA.sub.l).sub.l =peptide chains having the same or different amino acid residues; i and j =integers 0-20; m =an integer 1-10; n=an integer 2-10; Cx =a conjugator bearing at least two amine residues in a molecule having 1-30 carbon atoms, i.e, diamines, triamines, tetramines, and polyamines, which can have other functional groups in the molecule; Cy =a conjugator bearing at least two carboxyl residues in a molecule having 1-30 carbon atoms, i.e., aliphatic, aromatic, heteroaromatic, cycloalkyl dicarboxylic acid, tricarboxylic acid, and polycarboxylic acid residues, which can have other functional groups in the molecule; Cz .sup.= a conjugator bearing at least one amine residue and one carboxyl residue in an aromatic or a cycloalkyl skeleton, having 1-30 carbon atoms, i.e., aromatic, heteroaromatic and cycloalkyl amino carboxylic acid, diamino carboxylic acid, diamino dicarboxylic acid, and ployamino polycarboxylic acid residues; R.sub.1 =an alkyl, aromatic, heteroaromatic, or cycloalkyl group having 1-30 carbons, which can have other functional groups in the molecule; and Z=carboxyl, amide, N-substituted amide, hydrazide, N-substituted hydrazide, or ester group.

6. 发明授权

US09341637B2 Controlled platelet activation to monitor therapy of ADP antagonists 有权
公开(公告)号：US09341637B2
公开(公告)日：2016-05-17
申请号：US12943413
申请日：2010-11-10
申请人： Barry S. Coller , Dennis Durbin
发明人： Barry S. Coller , Dennis Durbin
IPC分类号： G01N33/86
CPC分类号： G01N33/86
摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

7. 发明授权

US09066948B2 Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines 有权
标题翻译：氧杂双环[3,2-a]嘧啶和噻二唑并[3,2-a]嘧啶
公开(公告)号：US09066948B2
公开(公告)日：2015-06-30
申请号：US13810587
申请日：2011-07-15
申请人： Barry S. Coller , Craig Thomas , Marta Filizola , Joshua McCoy , Wenwei Huang , Min Shen
发明人： Barry S. Coller , Craig Thomas , Marta Filizola , Joshua McCoy , Wenwei Huang , Min Shen
IPC分类号： A01N43/90 , A61K31/519 , C07D487/04 , A61K31/497 , A61K45/06 , C07D513/04
CPC分类号： A61K31/519 , A61K31/497 , A61K45/06 , C07D487/04 , C07D513/04 , A61K2300/00
摘要： The present invention relates to compounds of formula P-1 and related compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of A, Y, R1, R2, Ra, Ra′, Rb, Rb′, Rc, Rc′, Rd, Rd′, Re, and Re′ are provided herein. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
摘要翻译：本发明涉及式P-1化合物及其相关化合物和用于抑制和/或减少血小板沉积，粘附和/或聚集的组合物。本文提供了A，Y，R1，R2，Ra，Ra'，Rb，Rb'，Rc，Rc'，Rd，Rd'，Re和Re'的定义。本发明还涉及用于治疗或预防血栓形成障碍的方法，包括中风，心肌梗死，不稳定型心绞痛，外周血管疾病，血管成形术或支架放置后的突然闭合以及血管手术导致的血栓形成。

8. 发明授权

US5976532A Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3 失效
标题翻译：使用抗GPIIb / IIIa抗体或其片段（包括c7E3）进行抗血栓治疗的方法
公开(公告)号：US5976532A
公开(公告)日：1999-11-02
申请号：US443374
申请日：1995-05-17
申请人： Barry S. Coller , David M. Knight
发明人： Barry S. Coller , David M. Knight
IPC分类号： A61K38/00 , A61P7/02 , C07K16/28 , C12N15/13 , A61K39/395 , A61K38/49 , C12N9/64
CPC分类号： C07K16/2848 , A61K38/00 , C07K2317/24 , C07K2317/55 , C07K2319/00 , C07K2319/30 , C07K2319/33
摘要： Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
摘要翻译：描述血小板特异性，嵌合免疫球蛋白和免疫球蛋白片段。嵌合分子由非人抗原结合区和人恒定区组成。优选的免疫球蛋白对其复合形式的糖蛋白IIb / IIIa受体是特异性的; 它们阻断配体结合受体并防止血小板聚集。当单独或联合溶栓剂以及血栓成像时，免疫球蛋白可用于抗血栓形成治疗。

9. 发明授权

US5877006A DNAs encoding chimeric immunoglobulin light or heavy chains and fragments thereof having variable regions derived from monoclonal antibody 7E3, and vectors and host cells comprising same 失效
标题翻译：编码具有来自单克隆抗体7E3的可变区的嵌合免疫球蛋白轻链或重链及其片段的DNA，以及包含其的载体和宿主细胞
公开(公告)号：US5877006A
公开(公告)日：1999-03-02
申请号：US443382
申请日：1995-05-17
申请人： Barry S. Coller , David M. Knight
发明人： Barry S. Coller , David M. Knight
IPC分类号： A61K38/00 , A61P7/02 , C07K16/28 , C12N15/13 , C07H21/04 , C12N15/63
CPC分类号： C07K16/2848 , A61K38/00 , C07K2317/24 , C07K2317/55 , C07K2319/00 , C07K2319/30 , C07K2319/33
摘要： Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
摘要翻译：描述血小板特异性，嵌合免疫球蛋白和免疫球蛋白片段。嵌合分子由非人抗原结合区和人恒定区组成。优选的免疫球蛋白对其复合形式的糖蛋白IIb / IIIa受体是特异性的; 它们阻断配体结合受体并防止血小板聚集。当单独或联合溶栓剂以及血栓成像时，免疫球蛋白可用于抗血栓形成治疗。

10. 发明授权

US5336618A Fibrinogen blocking monoclonal antibody 失效
标题翻译：纤维蛋白原阻断单克隆抗体
公开(公告)号：US5336618A
公开(公告)日：1994-08-09
申请号：US274627
申请日：1988-11-22
申请人： Barry S. Coller
发明人： Barry S. Coller
IPC分类号： G01N33/53 , A61K38/00 , A61K39/395 , A61K51/00 , A61K51/10 , C07K14/005 , C07K14/195 , C07K16/00 , C07K16/28 , C12N5/10 , C12N5/20 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/577 , C07K15/28
CPC分类号： A61K51/1093 , A61K51/10 , C07K16/28 , A61K2123/00 , A61K38/00
摘要： There is provided a novel monoclonal antibody of the class IgG.sub.1 which reacts readily with both normal human and dog blood platelets while failing to react with thrombasthenic human platelets. This antibody has the property of completely blocking interaction of fibrinogen with platelets induced by ADP.
摘要翻译：提供了类IgG1的新型单克隆抗体，其与正常人和狗血小板容易反应，同时不能与血栓形成的人血小板反应。该抗体具有完全阻断纤维蛋白原与ADP诱导的血小板相互作用的性质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式